Article
Oncology
Keita Kawakado, Kazuhisa Nakashima, Hiroshi Tobita, Mamiko Nagase, Ken Yoshihara, Mika Horie, Megumi Hamaguchi, Tamio Okimoto, Yukari Tsubata, Takeshi Isobe
Summary: An 82-year-old man with malignant pleural mesothelioma was treated with ipilimumab and nivolumab. Despite previous treatment with prednisolone for immune-related adverse event hepatitis, his liver function worsened. After trying different medications, a combination of mercaptopurine and prednisolone improved his liver function and allowed for the gradual reduction of prednisolone dose. This case highlights the potential effectiveness of thiopurine-based immunosuppressants for steroid-refractory hepatitis.
Article
Health Care Sciences & Services
Sarahi Valdez-Acosta, Pablo Zubiaur, Miguel Angel Casado, Jesus Novalbos, Ana Casajus, Diana Campodonico, Itziar Oyaguez, Francisco Abad-Santos
Summary: A cost analysis of thiopurine treatment in 257 patients showed that preemptive genotyping and physician adherence to genotype-informed therapeutic recommendations significantly reduced healthcare costs and prevented myelotoxicity. Patients retrospectively genotyped had higher healthcare costs compared to preemptively genotyped patients. Intermediate metabolizers had significantly higher healthcare costs compared to normal metabolizers.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Evelien M. J. Beelen, Daan Nieboer, Jeanine H. C. Arkenbosch, Miguel D. Regueiro, Jack Satsangi, Sandro Ardizzone, Antonio Lopez-Sanroman, Edoardo Savarino, Alessandro Armuzzi, C. Janneke van der Woude, Annemarie C. de Vries
Summary: This meta-analysis found that anti-TNF-alpha treatment is superior to thiopurine prophylaxis for preventing endoscopic and clinical recurrence of Crohn's disease after ileocolonic resection. This advantage was confirmed in subgroup analysis and after risk stratification.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Garth R. Swanson, Mary Biglin, Hannah Raff, Vijit Chouhan, Sarah Jochum, Maliha Shaikh, Lauren Francey, Faraz Bishehsari, John Hogenesch, Ali Keshavarzian
Summary: Chronotherapy is a method of timing medication to optimize drug efficacy and minimize toxicity according to the biological rhythms of the host. This study found that morning dosing resulted in better metabolite profiles, and host chronotype could help identify patients who would benefit from evening dosing.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Gerard Grau, Eduard Brunet-Mas, Laura Patricia Llovet, Patricia Pedregal, Albert Villoria, Luigi Melcarne, Anna Puy, Belen Garcia-Sague, Luis Enrique Frisancho, Maria Jose Ramirez-Lazaro, Sergio Lario, Xavier Calvet
Summary: Thiopurines are a safe and effective treatment for maintaining remission in inflammatory bowel disease, with minimal adverse effects, especially after the first few months of treatment. This study suggests that regular analytic follow-up may not be necessary after the initial period of treatment.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Chemistry, Analytical
Marta Orts-Arroyo, Isabel Castro, Jose Martinez-Lillo
Summary: The study presents a stable diruthenium(III) compound capable of detecting hypoxanthine molecule reliably, prepared from different starting materials. The sensitivity, repeatability, and stability of this system make it potentially useful for developing new sensor devices to detect hypoxanthine.
Article
Reproductive Biology
Maria Regina Gomes-Carneiro, Rosangela Ribeiro de Carvalho, Thamyris Figueiredo do Amaral, Ana Cecilia Amado Xavier De-Oliveira, Francisco Jose Roma Paumgartten
Summary: This study found that 6MMPr affects embryonic development in rats. At normal doses, 6MMPr did not cause embryotoxicity, but at high doses, it may lead to slight embryolethality and reduced fetal weight. In comparison, 6MP caused higher damage to the embryos.
REPRODUCTIVE TOXICOLOGY
(2022)
Review
Health Care Sciences & Services
Yoichi Tanaka, Yoshiro Saito
Summary: Thiopurines are immunosuppressants used for various conditions, but can lead to severe adverse reactions. NUDT15 gene polymorphisms have been identified to play a crucial role in predicting adverse reactions to thiopurines in Asian populations.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Multidisciplinary Sciences
Maciej Noga, Marcin Zakrzewski, Dorota Wianowska, Maciej Gnatowski, Lukasz Paprotny, Kamil Jurowski
Summary: 6-Thioguanine is an immunosuppressive drug used to treat acute leukemia and inflammatory bowel disease. Accurate quantification of 6-Thioguanine in body fluids is essential for effective clinical application. A validated HPLC method has been developed to measure 6-Thioguanine in whole blood samples, providing a reliable approach for drug level monitoring and correct dosing.
SCIENTIFIC REPORTS
(2023)
Article
Gastroenterology & Hepatology
Cumali Efe, Craig Lammert, Koray Tascilar, Renumathy Dhanasekaran, Berat Ebik, Fatima Higuera-de la Tijera, Ali R. Caliskan, Mirta Peralta, Alessio Gerussi, Hatef Massoumi, Andreea M. Catana, Tugrul Purnak, Cristina Rigamonti, Andres J. G. Aldana, Nidah Khakoo, Leyla Nazal, Shalom Frager, Nurhan Demir, Kader Irak, Zeynep Melekoglu-Ellik, Huseyin Kacmaz, Yasemin Balaban, Kadri Atay, Fatih Eren, Mario R. Alvares-da-Silva, Laura Cristoferi, Alvaro Urzua, Tugce Eskazan, Bianca Magro, Romee Snijders, Sezgin Barutcu, Ellina Lytvyak, Godolfino M. Zazueta, Aylin Demirezer-Bolat, Mesut Aydin, Alexandra Heurgue-Berlot, Eleonora De Martin, Nazim Ekin, Sumeyra Yildirim, Ahmet Yavuz, Murat Biyik, Graciela C. Narro, Murat Kiyici, Murat Akyildiz, Evrim Kahramanoglu-Aksoy, Maria Vincent, Rotonya M. Carr, Fulya Gunsar, Eira C. Reyes, Murat Harputluoglu, Costica Aloman, Nikolaos K. Gatselis, Yucel Ustundag, Javier Brahm, Nataly C. E. Vargas, Fatih Guzelbulut, Sandro R. Garcia, Jonathan Aguirre, Margarita Anders, Natalia Ratusnu, Ibrahim Hatemi, Manuel Mendizabal, Annarosa Floreani, Stefano Fagiuoli, Marcelo Silva, Ramazan Idilman, Sanjaya K. Satapathy, Marina Silveira, Joost P. H. Drenth, George N. Dalekos, David N. Assis, Einar Bjornsson, James L. Boyer, Eric M. Yoshida, Pietro Invernizzi, Cynthia Levy, Aldo J. Montano-Loza, Thomas D. Schiano, Ezequiel Ridruejo, Staffan Wahlin
Summary: The study found that AIH patients who were on systemic glucocorticoids or thiopurines before the onset of COVID-19 had significantly worse severity of the disease, while those on baseline treatment with mycophenolate mofetil or tacrolimus also experienced more severe COVID-19 courses in a smaller subset of treated patients.
LIVER INTERNATIONAL
(2022)
Article
Oncology
Noha Abdel-Wahab, Adi Diab, Robert K. Yu, Andrew Futreal, Lindsey A. Criswell, Jean H. Tayar, Ramona Dadu, Vickie Shannon, Sanjay S. Shete, Maria E. Suarez-Almazor
Summary: The study identified multiple genetic variants associated with immune-related adverse events (irAEs), some of which increased the risk of irAEs while others decreased it. These variants help explain why some patients have different toxic responses to immune checkpoint inhibitors (ICIs). Additional larger studies are needed to validate and establish the functional relevance of these findings.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Daniel Rehling, Si Min Zhang, Ann-Sofie Jemth, Tobias Koolmeister, Adam Throup, Olov Wallner, Emma Scaletti, Takaya Moriyama, Rina Nishii, Jonathan Davies, Matthieu Desroses, Sean G. Rudd, Martin Scobie, Evert Homan, Ulrika Warpman Berglund, Jun J. Yang, Thomas Helleday, Pal Stenmark
Summary: The newly discovered NUDT15 inhibitor TH7755 has shown improved potency and specificity compared to TH1760, enhancing the effects of thiopurines without causing cytotoxicity. This potent inhibitor also stabilized NUDT15, allowing for analysis by X-ray crystallography to provide insights into the structural basis for thiopurine intolerance in patients with pharmacogenetic variants.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2021)
Article
Medical Laboratory Technology
Sofia A. W. van Moorsel, Debbie S. Deben, Rob H. Creemers, Bjorn Winkens, Paul Bus, Marieke J. Pierik, Melek Simsek, Nanne K. H. de Boer, Adriaan A. van Bodegraven, Dennis R. Wong
Summary: This study aimed to validate and optimize predictive algorithms for thiopurine-associated hepatotoxicity, but found limited accuracy in predicting liver toxicity. Factors contributing to this outcome included changes in prescription behavior over time and lower dosages of MP being prescribed.
THERAPEUTIC DRUG MONITORING
(2022)
Review
Pharmacology & Pharmacy
Anuraag Jena, Daya Krishna Jha, Praveen Kumar-M, Kripa Shanker Kasudhan, Ankit Kumar, Dhruv Sarwal, Shubhra Mishra, Anupam Kumar Singh, Prateek Bhatia, Amol Patil, Vishal Sharma
Summary: In the South Asian population, NUDT15 polymorphisms are more prevalent than TPMT and are more frequently associated with adverse events. These findings suggest the importance of preemptive testing for NUDT15 among South Asian population and immigrants before starting thiopurines.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Review
Obstetrics & Gynecology
Maya Frank Wolf, Ronen Sloma, Luiza Akria, Eli Rimon, Yifat Wiener, Michal Carmiel Haggai, Lior Lowenstein
Summary: This study reported a unique case of severe intrahepatic cholestasis of pregnancy induced by 6-mercaptopurine, and investigated the impact of azathioprine-related cholestasis on pregnancy complications and outcomes.
TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Alessandra Giuliano, Walter Fries, Anna Viola, Alfredo Abbruzzese, Maria Cappello, Enrica Giuffrida, Lucio Carrozza, Antonino Carlo Privitera, Antonio Magnano, Concetta Ferracane, Giuseppe Scalisi, Maria Giovanna Minissale, Emiliano Giangreco, Serena Garufi, Carmelo Bertolami, Ugo Cucinotta, Francesco Graziano, Angelo Casa, Sara Renna, Giulia Teresi, Giulia Rizzuto, Mariella Mannino, Marcello Maida, Ambrogio Orlando
Summary: This retrospective study found that severe inflammatory bowel disease was an independent risk factor for severe COVID-19. Patients with inflammatory bowel disease did not have a higher risk of SARS-CoV-2 infection compared to the general population, and a worse prognosis was not typically associated with immunomodulatory drugs.
INFLAMMATORY BOWEL DISEASES
(2023)
Letter
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Ambrogio Orlando
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Mariabeatrice Principi, Federica Facciotti, Antonella Contaldo, Alessia Todeschini, Simone Saibeni, Cristina Bezzio, Fabiana Castiglione, Olga Maria Nardone, Rocco Spagnuolo, Massimo Claudio Fantini, Gaia Riguccio, Flavio Caprioli, Chiara Vigano, Carla Felice, Gionata Fiorino, Carmen Correale, Giorgia Bodini, Monica Milla, Giulia Scardino, Marta Vernero, Federico Desideri, Mariella Mannino, Giuseppe Rizzo, Ambrogio Orlando
Summary: The study investigated the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) treated with immunomodulatory or biological drugs. The majority of IBD patients showed seropositivity after COVID-19 vaccination, but the magnitude of the humoral response was significantly lower compared to healthy controls. These findings suggest that the lower response is mostly unrelated to the use of immune-modifying treatments.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Mauro Grova, Marica Saladino, Maria Cappello, Maria Giulia Demarzo, Antonino Carlo Privitera, Emiliano Giangreco, Serena Garufi, Sara Renna, Angelo Casa, Marco Ventimiglia, Walter Fries, Ambrogio Orlando
Summary: This study assessed the effectiveness of Ustekinumab (UST) and Vedolizumab (VDZ) as third-line biologic therapy in patients with Crohn's disease (CD) and found that both treatments were highly effective.
DIGESTIVE AND LIVER DISEASE
(2023)
Letter
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Angelo Casa, Sara Renna, Mauro Grova, Mariella Mannino, Ambrogio Orlando
DIGESTIVE AND LIVER DISEASE
(2023)
Editorial Material
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Ambrogio Orlando
Summary: This article is linked to Caldera et al papers.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Stefanos Bonovas, Fabio Salvatore Macaluso, Daniele Piovani, Claudio Papi, Ambrogio Orlando, Alessandro Armuzzi
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Claudio Papi, Ambrogio Orlando, Stefano Festa, Daniela Pugliese, Stefanos Bonovas, Claudia Pansieri, Daniele Piovani, Gionata Fiorino, Massimo Claudio Fantini, Flavio Caprioli, Marco Daperno, Alessandro Armuzzi
Summary: A cure for Crohn's disease is currently unavailable, so lifelong management is necessary. Different biological drugs have been approved, including monoclonal antibodies targeting inflammatory pathways and adipose-derived stromal cells for perianal fistula. Italian guidelines on the use of biologics for managing CD have been issued, providing recommendations for different clinical settings. The recommendations are based on evidence from real world studies.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Marco Ventimiglia, Ambrogio Orlando
Summary: This study comprehensively summarized the effectiveness and safety of vedolizumab in patients with Crohn's disease (CD) and ulcerative colitis (UC) based on pooled data from observational studies. The results showed that vedolizumab had high rates of clinical remission in both induction and maintenance phases for CD and UC patients, with a low incidence rate of adverse events.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Mauro Grova, Filippo Mocciaro, Roberto Di Mitri, Antonino Carlo Privitera, Maria Emanuela Distefano, Alessandro Vitello, Salvatore Camilleri, Concetta Ferracane, Dario Pluchino, Nunzio Belluardo, Emiliano Giangreco, Walter Fries, Anna Viola, Maria Cappello, Livia D'Amato, Carmelo Bertolami, Marco Ventimiglia, Sara Renna, Angelo Casa, Elvira D'Antonio, Simona De Vivo, Ambrogio Orlando
Summary: According to the study, ustekinumab shows promising results in treating postoperative recurrence of Crohn's disease. This highlights the importance of ustekinumab as a treatment option for CD patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Mariabeatrice Principi, Federica Facciotti, Antonella Contaldo, Alessia Todeschini, Simone Saibeni, Cristina Bezzio, Fabiana Castiglione, Olga Maria Nardone, Rocco Spagnuolo, Massimo Claudio Fantini, Gaia Riguccio, Simone Conforti, Flavio Caprioli, Chiara Vigano, Carla Felice, Gionata Fiorino, Carmen Correale, Giorgia Bodini, Monica Milla, Giulia Scardino, Marta Vernero, Federico Desideri, Fabrizio Bossa, Maria Guerra, Marco Ventimiglia, Angelo Casa, Giuseppe Rizzo, Ambrogio Orlando
Summary: This prospective study has shown that a lack of seroconversion after receiving two doses of COVID-19 vaccines is a significant predictor of SARS-CoV-2 infection. Additionally, the treatments for inflammatory bowel disease (IBD) do not increase the risk of SARS-CoV-2 infection.
INFLAMMATORY BOWEL DISEASES
(2023)
Meeting Abstract
Gastroenterology & Hepatology
A. Todeschini, F. S. Macaluso, A. Contaldo, M. Mannino, A. Orlando, M. Principi
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
A. Todeschini, F. S. Macaluso, A. Contaldo, M. Mannino, A. Orlando, M. Principi
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
M. Grova, F. Crispino, M. Maida, A. Vitello, L. Tese, G. Rizzuto, A. Casa, S. Renna, F. S. Macaluso, A. Orlando
JOURNAL OF CROHNS & COLITIS
(2022)
Meeting Abstract
Gastroenterology & Hepatology
M. Grova, F. Crispino, M. Maida, A. Vitello, L. Tese, G. Rizzuto, A. Casa, S. Renna, F. S. Macaluso, A. Orlando
JOURNAL OF CROHNS & COLITIS
(2022)
